There is a provenge clinical trial which is currently recruiting participants. Remember, as with all trials, you must fit all of the criteria to participate. This trial does not use a placebo, you are guaranteed to receive the treatment if you are approved to participate. The trial sites are: * Park Ridge, Illinois * Greenbelt, [...]
There was just a release of some of the data from the on-going review sipuleucel-T, or Provenge, in men with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic prostate cancer. The data wes presented by Oregon Health & Realm University Cancer [...]
Yesterday’s New York Times article about health care reform and the overly inflated cost of the American health care system should ring large and loud alarm bells in the prostate cancer community. This article, along with the recent increasing pressure to halt prostate cancer screening, should put a major scare into the community. Unfortunately, the [...]
Is there going to be a competitor to Provenge once it is approved? This is a very interesting question as a second investigational vaccine has shown a significant survival advantage in men with asymptomatic metastatic castration-resistant prostate cancer. There were just released updated results from a phase II trial of PROSTVAC-VF/Tricom vaccine. The trial had [...]
Prior to the AUA meeting Dendreon released the following to its investors. We will now wait to see what transpires at the AUA meeting which is scheduled to be held in one and a half hours from my posting this. Joel T Nowak MA, MSW – Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival [...]